Abstract 13935: Predictors for the Improvement of Cardiac Symptoms After Renal Stenting; Multicenter Retrospective (PREMIERE) Registry Study
Background: There have been limited data available regarding response of renal artery stenting for cardiac disturbance syndrome (CDS) in atherosclerotic renal artery stenosis (ARAS) patients. The PREMIERE registry was a multicenter, retrospective study to clarify predictors for the improvement of cardiac symptoms after renal stenting.
Methods and Results: We enrolled 51 ARAS patients with CDS undergoing successful renal artery stenting (age 73.3±1.43, 30 males) from 11 hospitals in Japan between January 2000 and August 2015. The improvement of cardiac symptoms evaluated by NYHA functional class was observed in 86.3% (44 patients). According to a univariate analysis, eGFR and echocardiographic indices such as interventricular septal wall thickness (IVS) and early transmitral flow velocity were significantly (P<0.05) associated with the improvement of cardiac symptoms. Stepwise multivariate analysis using those variables with P<0.15 identified IVS as an independent predictor (Odds ratio 0.29; P=0.039). According to receiver operating characteristic (ROC) curve analysis, IVS cut off of 11.9 mm provided the best predictive value with a sensitivity of 78.4% and a specificity of 79.5% (Figure).
Conclusion: The present multicenter, retrospective study demonstrated that echocardiographic indice of IVS was a potential clinical predicator for the improvement of cardiac symptoms after renal artery stenting.
Author Disclosures: Y. Narishige: None. O. Kawarada: Honoraria; Modest; Terumo, Boston Scientific, Cook, Johnson & Johnson, Kaneka Medics, Sanofi K.K., Otsuka, MSD K.K., Takeda Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Pfizer Japan Inc. S. Sakamoto: None. K. Harada: None. T. Noguchi: None. H. Ogawa: Other Research Support; Modest; Astellas Pharma Inc, Bristol-Myers Squibb Company, Chugai Pharmaceutical Co, Ltd., Dainippon Sumitomo Pharma Co., Ltd., MSD K.K., Mochida Pharmaceutical Co., Ltd.. Other Research Support; Significant; Bayer, Daiichi Sankyo Co., Ltd.. Honoraria; Modest; AstraZeneca K.K., Boehringer Ingelheim Japan, Bristol-Myers Squibb Company, Mitsubishi Tanabe Pharma, Pfizer Japan Inc, Sanofi K.K., Teijin Pharma Co., Ltd, Ono Pharmaceutical Co., Ltd., Otsuka, Pfizer Japan Inc, Takeda Pharmaceutical Co., Ltd.. Honoraria; Significant; Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., MSD K.K., Takeda Pharmaceutical Co., Ltd., Novartis Pharma K.K., Sanofi K.K. S. Yasuda: Research Grant; Modest; Takeda, Otsuka, Bristol-Myers, Boehringer Ingel.. Honoraria; Modest; Takeda, Daiichi-Sankyo, Astra-Zeneca, Bristol-Myers.
- © 2015 by American Heart Association, Inc.